Azenta Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Azenta is gedaald met een gemiddeld jaarlijks percentage van -42.5%, terwijl de winst van de Life Sciences -industrie jaarlijks groeide met 11.7%. De inkomsten zijn groeide met een gemiddeld percentage van 5% per jaar.

Belangrijke informatie

-42.5%

Groei van de winst

-49.9%

Groei van de winst per aandeel

Life Sciences Groei van de industrie	21.5%
Inkomstengroei	5.0%
Rendement op eigen vermogen	-9.3%
Nettomarge	-25.0%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

Nov 17

Opbrengsten en kosten

Hoe Azenta geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:AZTA Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	656	-164	303	34
30 Jun 24	659	-156	301	34
31 Mar 24	652	-152	302	35
31 Dec 23	641	-17	297	35
30 Sep 23	665	-13	311	34
30 Jun 23	630	-21	302	33
31 Mar 23	597	-26	285	30
31 Dec 22	594	-25	279	29
30 Sep 22	555	-11	247	28
30 Jun 22	555	-28	267	26
31 Mar 22	551	-23	267	25
31 Dec 21	535	-29	261	24
30 Sep 21	514	-29	252	22
30 Jun 21	114	-69	183	-10
31 Mar 21	205	-53	185	-2
31 Dec 20	296	-37	183	9
30 Sep 20	389	-26	190	18
30 Jun 20	850	41	232	59
31 Mar 20	834	28	224	59
31 Dec 19	812	16	217	58
30 Sep 19	334	-61	157	17
30 Jun 19	741	3	194	54
31 Mar 19	710	7	182	51
31 Dec 18	668	72	170	49
30 Sep 18	632	68	163	47
30 Jun 18	488	35	154	41
31 Mar 18	498	47	149	40
31 Dec 17	510	-2	146	40
30 Sep 17	527	11	141	40
30 Jun 17	669	56	136	46
31 Mar 17	634	47	132	47
31 Dec 16	600	-51	127	49
30 Sep 16	434	-85	116	44
30 Jun 16	549	-73	123	52
31 Mar 16	546	-74	119	52
31 Dec 15	550	12	117	52
30 Sep 15	553	14	114	52
30 Jun 15	529	8	112	53
31 Mar 15	502	-3	112	54
31 Dec 14	489	-3	111	54
30 Sep 14	483	1	110	53
30 Jun 14	471	3	107	51
31 Mar 14	464	10	102	49
31 Dec 13	448	5	97	48

Kwaliteitswinsten: AZTA is momenteel verliesgevend.

Groeiende winstmarge: AZTA is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: AZTA is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 42.5% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van AZTA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: AZTA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Life Sciences industrie ( -4.7% ).

Rendement op eigen vermogen

Hoge ROE: AZTA heeft een negatief Return on Equity ( -9.28% ), omdat het momenteel verliesgevend is.

Azenta Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2024 earnings: EPS misses analyst expectations

Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024

Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Independent Director recently bought US$495k worth of stock

Consensus revenue estimates decrease by 14%

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

Price target decreased by 7.2% to US$56.60

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Full year 2024 earnings: EPS misses analyst expectations

Azenta, Inc. Announces Chief Financial Officer Changes

Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024

Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Azenta: Life Science Play Is Not Coming To Life

Azenta, Inc. Announces Management Changes

Price target decreased by 7.2% to US$58.25

Consensus EPS estimates fall by 29%

Forecast to breakeven in 2026

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024

Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024

Stephen Schwartz to Retire as CEO of Azenta, Inc

Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024

Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?

Now 20% overvalued

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Consensus EPS estimates fall by 20%

New major risk - Revenue and earnings growth

Senior VP notifies of intention to sell stock

Consensus EPS estimates fall by 19%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Azenta, Inc. Announces the Launch of the BioArc Ultra

Price target increased by 9.9% to US$72.00

Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Key Executive notifies of intention to sell stock

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 20%

Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023

Is There An Opportunity With Azenta, Inc.'s (NASDAQ:AZTA) 31% Undervaluation?

Politan Capital Provides Information to the Shareholders

Consensus EPS estimates upgraded to US$0.39 loss

Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023

Politan Capital Management Engages in Discussions with Azenta

Politan Capital Management Engages in Discussions with Azenta

At US$50.66, Is It Time To Put Azenta, Inc. (NASDAQ:AZTA) On Your Watch List?

Now 23% undervalued

New minor risk - Insider selling

Insider recently sold US$407k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023

Estimating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Consensus EPS estimates upgraded to US$0.49 loss

Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023

Now 20% undervalued

Independent Chairman notifies of intention to sell stock

Is Azenta, Inc. (NASDAQ:AZTA) Potentially Undervalued?

Price target decreased by 13% to US$52.50

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 11%

Revenue Downgrade: Here's What Analysts Forecast For Azenta, Inc. (NASDAQ:AZTA)

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023